Micreos Group is the world’s leading developer of endolysin- and phage technology, as a sustainable alternative to antibiotics. This technology enables – for the first time – the targeted killing of only unwanted bacteria, regardless of resistance to antibiotics. The Micreos Group has pioneered the development of this technology and brought the world the first endolysin-based precision antibacterials. Micreos Group aims to contribute to mankind in many ways, as evidenced by its credo to Help as many as possible as soon as possible. Three separate businesses build on Micreos Group’s advanced technology. Phageguard is dedicated to food safety with products against food pathogens such as Listeria, Salmonella and E.Coli. The specialized skincare brand Gladskin helps hundreds of thousands of people living with inflammatory skin conditions such as eczema, rosacea and acne. The pharmaceutical activities, conducted by Swiss based Micreos AG, lead the way in the clinical development of endolysins and phage technology against harmful bacteria (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T- cell Lymphoma. The Micreos Group’s head office is based in The Hague, NL. The pharmaceutical branch Micreos has headquarters in Zug, CH, a Discovery and Technology Center in Wädenswil, CH, and a Development Team in Bilthoven, NL. Gladskin is based in the Netherlands, with offices in the USA and Germany. Phageguard is based in Wageningen, NL.